XNAS
PALI
Market cap256mUSD
Oct 08, Last price
1.45USD
1D
-2.03%
1Q
-26.02%
Jan 2017
-100.00%
IPO
-100.00%
Name
Palisade Bio Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
197.87%
Rev. gr., 5y
-0.78%
Revenues
0
Net income
-17m
L+16.23%
CFO
-11m
L-11.04%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Key people
Executive Chairman, Principal Executive Officer · since 2020
Matthew W. Kalnik
President, Chief Operating Officer · since 2020
David Recker
Chief Medical Officer · since 2017
Director · since 2019
Director · since 2019
Independent Director · since 2017
Scott V. Ogilvie
Independent Director · since 2008
Binxian Wei
Independent Director · since 2019
Stanley I. Westreich
Independent Director · since 2011
Legal address
C/O Paracorp Incorporated
2140 South DuPont Highway
Camden, DE 19934
US
2140 South DuPont Highway
Camden, DE 19934
US
Headquarters
2nd Floor
20271 Goldenrod Lane
Germantown, MD 20876
US
20271 Goldenrod Lane
Germantown, MD 20876
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||